Global Chemotherapy-Induced Acral Erythema Treatment Market Analysis By Treatment [(Medical Treatment (Analgesics, Anti-Inflammatory And Anti-Edematous Agents, Antihistaminic, NSAIDs, Oral/Topical Glucocorticoids, Pyridoxine (Vitamin B6), Others), Cold Compression Therapy, Others], By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: May 2024
- Report ID: 73929
- Number of Pages: 303
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
Chemotherapy-Induced Acral Erythema Treatment Market: Acral erythema, also known as a Hand-foot Syndrome (HFS) or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness), and desquamation (skin peeling) of the palms, soles, and, on rare occasions, the knees and elbows. Acryl erythema is a type of adverse medication reaction that occurs after several months of therapy with chemotherapeutic medicines, the most prevalent of which are gemcitabine and fluorouracil.
Chemotherapy-induced acryl erythema is a dose-dependent condition that can be treated by stopping chemotherapy or reducing the dosage. Symptomatic treatment with analgesics and antihistaminic medications to minimize pain, and edema is used to treat chemotherapy-induced acryl erythema.
According to the National Center for Biotechnology Information (NCBI), patients treated with capecitabine have a 60% chance of developing HFS.
On September 20, 2020, the Central National Investigations Oncology (CNIO) identified genetic variables linked to HFS in capecitabine chemotherapy.
Key Market Segments
Treatment
- Medical Treatment
- Analgesics
- Anti-Inflammatory And Anti-Edematous Agents
- Antihistaminic
- NSAIDs
- Oral/Topical Glucocorticoids
- Pyridoxine (Vitamin B6)
- Others
- Cold Compression Therapy
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Drivers
Increasing Incidence of Cancer
One of the primary drivers for the Chemotherapy-Induced Acral Erythema Treatment Market is the increasing incidence of cancer globally. As cancer rates rise, the use of chemotherapy as a primary treatment method also increases, subsequently boosting the demand for treatments addressing its side effects, such as acral erythema. This condition is a painful and often debilitating side effect, necessitating effective management solutions.
According to the World Health Organization (WHO), the global cancer burden is expected to rise to 19.3 million cases by 2025. This increase is likely to expand the use of chemotherapy, which is projected to drive up the incidence of chemotherapy-induced side effects, including acral erythema. For instance, approximately 10% of patients undergoing chemotherapy for certain cancers experience acral erythema, underscoring the need for effective treatment solutions.
Restraints
High Cost of Treatment
A major restraint in this market is the high cost of treatment options. Chemotherapy-induced acral erythema can require advanced therapeutic approaches, which are often expensive and may not be fully covered by insurance. This can limit access to necessary treatments for many patients, potentially hindering market growth.
The cost of managing side effects like chemotherapy-induced acral erythema can be significant. On average, treatment costs for managing severe cases can exceed $2,000 per patient, factoring in medications, specialist consultations, and ongoing care. These costs represent a substantial burden, particularly in regions with less comprehensive health insurance coverage, affecting treatment accessibility.
Opportunities
Advancements in Treatment Modalities
There is significant opportunity in the development of new and more effective treatment modalities. Innovation in pharmacological treatments, such as topical therapies or advanced biologics, can provide more effective and less invasive options for managing chemotherapy-induced acral erythema. This also includes potential developments in preventive treatments, reducing the incidence or severity of acral erythema in chemotherapy patients.
The market for chemotherapy-induced acral erythema treatments is poised for growth with the emergence of new pharmaceuticals. The U.S. Food and Drug Administration (FDA) has several drugs in Phase II clinical trials that promise to reduce the severity and duration of acral erythema. Successful development and approval of these drugs could significantly expand the treatment landscape.
Trends
Increasing Awareness and Patient Support
A notable trend in the market is the increasing awareness among healthcare providers and patients about the need for specialized treatments for chemotherapy-induced side effects. This awareness is being supported by more comprehensive patient education and the growth of support networks, both of which contribute to a better understanding of acral erythema and its management. Additionally, there is a trend towards personalized medicine, where treatments are tailored specifically to the needs of individual patients based on genetic, environmental, and lifestyle factors.
There is a growing recognition of the impact of chemotherapy side effects on patient quality of life, leading to enhanced patient education initiatives. For example, a survey conducted by the American Cancer Society found that 75% of oncologists now discuss potential side effects like acral erythema more frequently than they did five years ago. Furthermore, there is an increase in patient advocacy groups providing resources and support for chemotherapy patients, which helps in managing the psychological and physical burdens of treatment.
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Market Key Players
- Taro
- Oceanside Pharmaceuticals
- Pfizer
- Novartis
- A-S Medication Solutions
- Preferred Pharmaceuticals
- Syntex Pharmaceuticals
- Valeant Canada
- Technilab Pharma
- Allergan
Report Scope
Report Features Description Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Treatment [(Medical Treatment (Analgesics, Anti-Inflammatory And Anti-Edematous Agents, Antihistaminic, NSAIDs, Oral/Topical Glucocorticoids, Pyridoxine (Vitamin B6), Others), Cold Compression Therapy, Others], By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Taro, Oceanside Pharmaceuticals, Pfizer, Novartis, A-S Medication Solutions, Preferred Pharmaceuticals, Syntex Pharmaceuticals, Valeant Canada, Technilab Pharma, Allergan Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Chemotherapy-Induced Acral Erythema Treatment MarketPublished date: May 2024add_shopping_cartBuy Now get_appDownload Sample - Medical Treatment
- Taro
- Oceanside Pharmaceuticals
- Pfizer Inc Company Profile
- Novartis AG Company Profile
- A-S Medication Solutions
- Preferred Pharmaceuticals
- Syntex Pharmaceuticals
- Valeant Canada
- Technilab Pharma
- Allergan
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |